Showing 1861-1870 of 2050 results for "".
- Meet Zaffiro, Neauvia’s Two-Part Solution to Skin Rejuvenationhttps://modernaesthetics.com/news/meet-zaffiro-neuvias-two-part-solution-to-skin-rejuvenation/2472893/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuvenation system combining wa
- BTL Introduces Emsella Applicator for Emsculpt Platformhttps://modernaesthetics.com/news/btl-introduces-emsella-applicator-for-emsculpt-platform/2472892/BTL is launching the new Emsella applicator with up to 2.5 Tesla (T) to treat all forms of male and female urinary incontinence. Building upon the existing clearances for Emsculpt for the abdomen, buttocks, thighs, arms and calves, the new Emsella applicator makes Emsculpt the first system to tre
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- SkinMedica's DiamondGlow Hits Doctor's Officeshttps://modernaesthetics.com/news/skinmedicas-diamondglow-hits-doctors-offices/2472875/llergan’s Skinmedica is rolling out DiamondGlow, a non-invasive dermabrasion technology that exfoliates, extracts, and treats the face, eye area, lips and body. Allergan acquired Envy Medical, Inc and its Silkpeel&nbs
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Crown Aesthetics Adds ProGen PRP Advantage to Portfoliohttps://modernaesthetics.com/news/crown-aesthetics-adds-progen-prp-advantage-to-portfolio/2472870/ProGen PRP Advantage, an easy-to-use, single-spin system that features 15ml and 30ml tubes, yielding 7-15ml of 2x concentration PRP, is now available from Crown Aesthetics, a division of Crown Laboratories, Inc. With the launch of
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- New Data from Revian Red: System Shown to Support Hair Growthhttps://modernaesthetics.com/news/new-data-from-revian-red-system-shown-to-support-hair-growth/2472868/The Revian Red hair growth system demonstrates the ability to successfully stop hair loss and subsequently grow new hair, according to final data from a randomized, double-blind study. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii an